Salix, Santarus talk synergies, diversification; 2014 guidance provided

Salix Pharmaceuticals' (SLXP) deal for Santarus (SNTS) creates a specialty company with 22 marketed products and very little overlap.

Uceris, Glumetza, and Zegerid — which this quarter had sales of $19.6M, $45.6M, and $27.1M, respectively — should help SLXP diversify its revenue stream. In Q3, Xifaxan accounted for nearly 70% of the top-line.

The companies say that post-merger, "no product is expected to account for more than 50% of the combined company's revenue."

Combined company Q3 results: Revenue of $1.348B and adjusted EBITDA of $537M.

SLXP expects "revenue synergies from the increased number of sales representatives in GI and the expanded presence in primary care."

FY14 combined company outlook: Adjusted EPS of $5. (PR)

See also: SNTS Q3 results, SLXP Q3 results

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs